NexImmune, Inc. Common Stock (NEXI)

Etorro trading 970x250

About NexImmune, Inc. Common Stock

NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation (AIM) technology. The company has two product candidates in human trials, including NEXI-001 in acute myeloid leukemia, or AML; and NEXI-002 in multiple myeloma, or MM. NexImmune, Inc. was founded in 2011 and is headquartered in Gaithersburg, Maryland. Address: 9119 Gaither Road, Gaithersburg, MD, United States, 20877

NexImmune, Inc. Common Stock News and around…

Latest news about NexImmune, Inc. Common Stock (NEXI) common stock and company :

NexImmune to Present at the 2021 Cantor Virtual Global Healthcare Conference
27 Sep, 2021 FinancialContent
NexImmune to Present at the Morgan Stanley 19th Annual Global Healthcare Conference
10 Sep, 2021 Yahoo! Finance

GAITHERSBURG, Md., Sept. 10, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced that Scott Carmer, Chief Executive Officer, will participate in a fireside chat during the Morgan Stanley 19th Annual Global Healthcare Conference today, September 10, 2021 at 1:15p.m. Eastern time. The webca

NexImmune to Present at the Morgan Stanley 19th Annual Global Healthcare Conference
10 Sep, 2021 FinancialContent
54 Biggest Movers From Yesterday
26 Aug, 2021 FinancialContent

Gainers Regencell Bioscience Holdings Limited (NASDAQ: RGC) shares jumped 202.8% to settle at $46.33 on Wednesday after gaining ...

Add Up The Parts: IWO Could Be Worth $374
25 Aug, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares Russell 2000 Growth ETF (IWO), we found that the implied analyst target price for the ETF based upon its underlying holdings is $374.01 per unit.

85 Biggest Movers From Yesterday
11 Aug, 2021 FinancialContent

Gainers Fulcrum Therapeutics, Inc. (NASDAQ: FULC) jumped 125.3% to close at $18.77 on Tuesday after the company announced positive ...

Bullish insiders bet US$4.1m on NexImmune, Inc. (NASDAQ:NEXI)
10 Aug, 2021 Yahoo! Finance

Over the last year, a good number of insiders have significantly increased their holdings in NexImmune, Inc...

NexImmune Reports Second Quarter 2021 Financial Results and Provides Business Updates
09 Aug, 2021 FinancialContent
NexImmune to Explore the Use of AIM™ Direct Injection Technology in Type 1 Diabetes
09 Aug, 2021 FinancialContent
The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight
08 Aug, 2021 FinancialContent

Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader ...

The Daily Biotech Pulse: Sanofi Buys Translate Bio In $3.2B Deal, Lilly's Q2 Earnings Disappoint, Bausch To Spin Off Medical Aesthetics Business
03 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Merck's Disappointing Q2, Atreca Falls On Data, FDA Nod For Viatris, Nuvalent, Icosavax IPOs
29 Jul, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal
28 Jul, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

NexImmune to Announce Second Quarter 2021 Financial Results and Provide Corporate Update on August 9, 2021
27 Jul, 2021 FinancialContent
Analysts Predict 22% Upside For The Holdings of IWO
22 Jul, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares Russell 2000 Growth ETF (IWO), we found that the implied analyst target price for the ETF based upon its underlying holdings is $369.43 per unit.

The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall Street
20 Jul, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Moderna To Join S&P 500 Index, Thumbs Down For FibroGen's Anemia Drug, Corvus Shelves COVID Study
16 Jul, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Galapagos Sinks On Data, J&J Recalls Sunscreen Products, FibroGen Awaits AdCom Verdict, 3 IPOs
15 Jul, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

NexImmune Strengthens Management Team with Key Appointments
14 Jul, 2021 FinancialContent
The Daily Biotech Pulse: Equillium Issues Positive Regulatory Update, Biogen In-Licenses Multiple Sclerosis Drug, Aridis Releases COVID-19 Antibody Cocktail Data
13 Jul, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Lilly, Morphic's Positive Data At ECCO, Humanigen's COVID Treatment Gets Expedited Review In UK, TransCode IPO
09 Jul, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Opiant Spikes On Data, OncoSec Rallies On Merck Collaboration, XBiotech Special Dividend
07 Jul, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Gemini Sinks On Data, Amgen's Migraine Drug Approved In Japan, Liver Congress Gets Underway
23 Jun, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Sanofi, Translate Bio Start Early Stage Seasonal Flu Vaccine Study, Dr. Reddy's Launches Generic Vascepa, Halozyme Strikes Licensing Deal
22 Jun, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

NexImmune to Present at the Raymond James 2021 Human Health Innovation Conference
16 Jun, 2021 FinancialContent
The Week Ahead In Biotech: Biogen, Alexion And Vertex FDA Decisions, Multiple Conference Presentations On The Deck
07 Jun, 2021 FinancialContent

Biopharma stocks advanced in the truncated week ended June 4 amid the broader market strength. The American Society for Clinical ...

The Week Ahead In Biotech: ASCO Presentations Front And Center, FDA Decisions Due For Scynexis, Liminal And Alkermes
31 May, 2021 FinancialContent

After having declined through the first half of the week, biotech stocks staged a recovery to close higher in the trading week ended May ...

NexImmune Announces Formation of Scientific Advisory Board
27 May, 2021 FinancialContent
NexImmune Announces Presentation of Preliminary Phase 1/2 Clinical Data at the 2021 American Society of Clinical Oncology Annual Meeting
19 May, 2021 FinancialContent
NexImmune Reports First Quarter 2021 Financial Results and Recent Updates
17 May, 2021 FinancialContent

NexImmune, Inc. Common Stock (NEXI) is a NASDAQ Common Stock listed in , ,

970x250